Daisuke Takahari

BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer

Tomoya Yokota, Takashi Ura, Norio Shibata et al. · British Journal of Cancer · 2011 · 411 citations · Full text

Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial

Charles S. Fuchs, Kohei Shitara, Maria Di Bartolomeo et al. · The Lancet Oncology · 2019 · 276 citations · Full text

First-line Therapy, Gastrointestinal Oncology, Medicine +6

Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial

Yasuhide Yamada, Daisuke Takahari, Hiroshi Matsumoto et al. · The Lancet Oncology · 2013 · 252 citations

Oncology, Randomised Phase 3, Bevacizumab Versus S-1 +8

Neuroendocrine tumors of the stomach: chemotherapy with cisplatin plus irinotecan is effective for gastric poorly-differentiated neuroendocrine carcinoma

Natsuko Okita, Ken Kato, Daisuke Takahari et al. · Gastric Cancer · 2011 · 126 citations · Full text

Surgical Oncology, Gastrointestinal Oncology, Medicine +7

A phase II study of preoperative chemotherapy with docetaxel, cisplatin, and S-1 followed by gastrectomy with D2 plus para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis: JCOG1002

Seiji Ito, Takeshi Sano, Junki Mizusawa et al. · Gastric Cancer · 2016 · 120 citations · Full text

Preoperative Chemotherapy, Surgical Oncology, Gastrointestinal Oncology +7